Evidence map›Paper›PMID 41385771›Full record

ReviewMagyar onkologia2025

[Management of immune-related cutaneous toxicities].

Eszter Baltás

Abstract readReviewEnglish Abstract
In one paragraph

Review in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Eszter BaltásSzent-Györgyi Albert Orvostudományi Kar, Szegedi Tudományegyetem, Bőrgyógyászati és Allergológiai Klinika, Szeged, Hungary. baltas.eszter@med.u-szeged.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune-related dermatologic side effects are among the most common and often the earliest toxicities of immunotherapies. Clinically, they cover a wide spectrum, ranging from mild skin symptoms to severe, life-threatening conditions. Most cases can be well managed with early recognition and personalized treatment. The dermatologist plays a key role in rapid diagnosis, therapeutic decision-making, and multidisciplinary oncological collaboration. The goal of supportive oncodermatology is, in addition to controlling side effects, to ensure the continuation of immunotherapy and to preserve the patient's quality of life.

Indexed as

Antineoplastic Agents, ImmunologicalDrug EruptionsImmune Checkpoint InhibitorsImmunotherapyNeoplasmsSkin DiseasesHumansQuality of LifeAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Identifiers

PMID41385771
PMCPMC12701782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.